No Data
No Data
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their
BioMarin Pharmaceutical Price Target Maintained With a $110.00/Share by Cantor Fitzgerald
BioMarin Pharmaceutical Price Target Maintained With a $110.00/Share by Cantor
Express News | Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past 20 years by 6.44% on an annualized basis producing an average annual return of 14.87%. Currently, Biomarin
Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Meliora Therapeutics ("Meliora"), a machine learning therapeutics company developing novel and transformative cancer drugs, today announced the appointment of Dieter